title: Acute High-Intensity Intermittent Aerobic Exercise Reduces Plasma Angiopoietin-Like 2 in Patients With Coronary Artery Disease.
abstract: BACKGROUND
  Circulating levels of angiopoietin-like 2 (ANGPTL2), a proinflammatory and proatherogenic protein, are elevated in patients with coronary artery disease (CAD). We hypothesized that high-intensity intermittent exercise (HIIE), known to be beneficial in patients with CAD, would reduce circulating ANGPTL2 levels.
  
  
  METHODS
  Plasma levels of ANGPTL2 were measured before and 20 minutes, 24 hours, and 72 hours after an acute exercise session in a crossover study comparing HIIE to moderate-intensity continuous exercise (MICE) in 14 patients with CAD and 20 age-matched and 20 young healthy controls.
  
  
  RESULTS
  Pre-exercise ANGPTL2 levels were 3-fold higher in patients with CAD than in age-matched controls (P < 0.05) and correlated negatively with Vo2max/lean body mass (P < 0.0001). In healthy controls, ANGPTL2 levels were low and not affected by HIIE or MICE. In patients with CAD, ANGPTL2 levels decreased significantly by 41% after 20 minutes of HIIE, a reduction that was maintained after 24 and 72 hours (P < 0.05). In contrast, although ANGPTL2 levels decreased by 47% after 20 minutes of MICE, they increased by 104% after 24 hours and returned to baseline values after 72 hours (P < 0.05). A negative correlation was observed between this increase in ANGPTL2 levels and the mean rate-pressure product (heart rate × systolic blood pressure; index of myocardial O2 consumption) measured during MICE, suggesting that subclinical ischemia might promote ANGPTL2 expression.
  
  
  CONCLUSIONS
  In patients with CAD, circulating ANGPTL2 levels are acutely reduced after HIIE and transiently increased after MICE. A sustained reduction in circulating ANGPTL2 levels could contribute to the chronic beneficial cardiometabolic effects of HIIE in patients with CAD.
authors.affiliation: Cardiac Rehabilitation and Prevention Center (EPIC) of the Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Larouche
authors.affiliation: Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada; Departments of Pharmacology and Surgery, Faculty of Medicine, University of Montreal, Montreal, Québec, Canada.
authors.forename: Carol
authors.initials: C
authors.lastname: Yu
authors.affiliation: Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Luo
authors.affiliation: Pharsight Corporation Canada, Montreal, Québec, Canada.
authors.forename: Nada
authors.initials: N
authors.lastname: Farhat
authors.affiliation: Cardiovascular and Pulmonary Rehabilitation Clinic of Saint-Orens, Saint-Orens, France.
authors.forename: Thibaut
authors.initials: T
authors.lastname: Guiraud
authors.affiliation: Cardiac Rehabilitation and Prevention Center (EPIC) of the Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Julie
authors.initials: J
authors.lastname: Lalongé
authors.affiliation: Cardiac Rehabilitation and Prevention Center (EPIC) of the Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Gayda
authors.affiliation: Cardiac Rehabilitation and Prevention Center (EPIC) of the Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Martin
authors.initials: M
authors.lastname: Juneau
authors.affiliation: Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, Québec, Canada.
authors.forename: Jean
authors.initials: J
authors.lastname: Lambert
authors.affiliation: Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Thorin-Trescases
authors.affiliation: Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada; Departments of Pharmacology and Surgery, Faculty of Medicine, University of Montreal, Montreal, Québec, Canada. Electronic address: eric.thorin@umontreal.ca.
authors.forename: Eric
authors.initials: E
authors.lastname: Thorin
authors.affiliation: Cardiac Rehabilitation and Prevention Center (EPIC) of the Montreal Heart Institute, University of Montreal, Montreal, Québec, Canada; Montreal Heart Institute, Research Center, University of Montreal, Montreal, Québec, Canada.
authors.forename: Anil
authors.initials: A
authors.lastname: Nigam
mesh_terms: D000368:Aged; D000091302:Angiopoietin-Like Protein 2; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins / Q000032:analysis / Q000378:metabolism; D001794:Blood Pressure; D003324:Coronary Artery Disease / Q000378:metabolism / Q000503:physiopathology; D018592:Cross-Over Studies; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test / Q000379:methods; D005260:Female; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000502:physiology
chemical_list: C485792:ANGPTL2 protein, human; D000091302:Angiopoietin-Like Protein 2; D000075802:Angiopoietin-like Proteins; D042682:Angiopoietins